Anti-CD19-liposomes encapsulated domain III of pseudomonas exotoxin in the targeting of human B lymphoma.
- Author:
Jie MA
1
;
Li-Ren CAO
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antigens, CD19; immunology; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Exotoxins; therapeutic use; Humans; Liposomes; Lymphoma; pathology; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; drug therapy; Pseudomonas; chemistry; Tumor Cells, Cultured; Xenograft Model Antitumor Assays
- From: Chinese Journal of Oncology 2003;25(1):36-38
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the targeting ability and cytotoxicity of domain III of pseudomonas exotoxin encapsulated in anti-CD19-immunoliposomes to lymphoma cells in vitro and in vivo.
METHODSBinding ability of anti-CD19 immunoliposomes to B lymphoma cells was detected by binding assay. MTT assay was used to detect the cytotoxicity of free domain III and domain III encapsulated in anti-CD19-immunoliposomes against B lymphoma cells. An in vivo therapeutic study of domain III formulated in immunoliposomes on human B lymphoma was detected in a murine model.
RESULTSThe cytotoxicity of free domain III disappeared when domain I and II were deleted. When domain III was encapsulated into anti-CD19-immunoliposomes, the cytotoxicity of immunoliposomes against tumor cells were significantly increased. Treatment, using this formulation, of mice inoculated with B lymphoma could enhance the survival time.
CONCLUSIONAnti-CD19-immunoliposomes, as drug carriers, can specifically recognize B lymphoma cells and deliver non-toxic domain III into the tumor cells. This formulation of domain III might be an effective anti-tumor agent.
